CLDX Projected Dividend Yield
Celldex Therapeutics, Inc. ( NASDAQ : CLDX )Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies. Co.'s clinical development programs include: CDX-0159, which is a human monoclonal antibody that specifically binds the receptor tyrosine kinase KIT; CDX-1140, which is a human monoclonal antibody targeted to CD40, a key activator of immune response, which is being studied in a Phase1 study; and CDX-527, which is a bispecific antibody that uses Co.'s proprietary anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which Co. has initiated a Phase 1 study in advanced solid tumors. 20 YEAR PERFORMANCE RESULTS |
CLDX Dividend History Detail CLDX Dividend News CLDX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |